Utility of 68 Ga-DOTA-Exendin-4 PET/CT imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia.
Victor Kalff, Amir Iravani, Timothy Ackhurst, David A Pattison, Peter Eu, Michael S Hofman, Rodney J Hicks
Internal Medicine Journal | Published : 2020
BACKGROUND: Because management is very different, it is important to differentiate between small focal insulinomas and diffuse pancreatic dysplasia (nesidioblastosis) in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia (EHH). Most insulinomas highly express Glucagon Like Peptide-1 receptors enabling PET/CT imaging with its radiolabelled analogue; 68 Ga-DOTA-exendin-4 (Exendin). AIM: To determine (a) the utility of Exendin in EHH patients in a clinical setting; (b) whether degree of Exendin uptake differentiates non-insulinoma pancreatogenous hypoglycaemia syndrome (NIPHS) from post gastric bypass hypoglycaemia (PGBH). METHODS: This retrospective study reviewed the clinical,..View full abstract